Sturlimogene Erparepvec

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameSturlimogene Erparepvec
Drug Alias NameGenetically modified herpes simplex type 1 virus (Replimune)RP-2
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsUveal melanomaEsophageal adenocarcinomaGastroesophageal Junction Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesReplimune Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesReplimune Inc
Inactive CompaniesN/A
Active IndicationsUveal melanomaEsophageal adenocarcinomaGastroesophageal Junction Neoplasms +[6] 
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A